Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whats the inside scoop?
Idk Cabin, I believe we all might be surprised this time.
Good luck to all of us.
Rephrase…. Another Q of something that keep us from being g profitable.
Likely another Q of disappointment.
Take care
You too my friend
Hopefully it's a good one
Q next week
We might see then. Fingers crossed 🤞
Can we get anything to confirm management still has a pulse? Everything I read tells me this company will be successful, besides the daily share price… In for the long haul with RXMD!
There's a little action today. Maybe fernandez placed that discreet tmall order.
Never Ending Story!! Certainly a classic Turbo. Even Atreyu knew when to walk away as Artax began sinking into the Swamp of Sadness tar pits.
Fernandez hosed A LOT of investors on both sides of the NXPL / RXMD coin.
You're telling me. I'm living it.
The never ending story - nostalgic
The never ending quiet period- nightmarish
Yikes! That sounds worse than a 3 year quiet period 😬
I hope the merger comes with a loud period!
Good Luck RXMD shareholders!
Good Luck NXPL shareholders!
$RXMD + $NXPL
He meant funball. It's a game you play behind the Wendy's dumpster.
Hey, What is Finbull?
Good Luck RXMD shareholders!
Good Luck NXPL shareholders!
$RXMD + $NXPL
I’ve been buying small amounts each week. It adds up.
Hey Mike! How is Finbull
I'll be adding another 1500 tomorrow.
HaHa...Bingo!!
Up sizing your extra value meal
Everything looks great! 2.8 million shares will get gobbled up fast on 100,000 volume days.
Such a small Public Float. You're right...this would jump so quickly.
Sure wished Mark Cuban would buy those shares up. Can you imagine how much this would fly? ( I know it's just wishful thinking, but wow).
Hopefully in the morning time
Thanks Garrox - Zero Debt, Public Float only 2.8 million shares. Not bad at all.
LOL!! Please define riches.
Should be out next week
Not real nice until the Share Price starts to climb. 🙂
No trade ? even everything is 50% off in rxmd store ???
Gedi has been hoarding all of the riches to himself.
I, Cecile Munnik, Chief Financial Officer of Progressive Care Inc. (“the Company”), certify that:
1. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (mark the box below that applies with an “X”):
REGISTERED or REPORTING WITH THE SEC:
[?] Company is registered under Section 12(g) of the Exchange Act
[?] Company is reporting under Section 15(d) of the Exchange Act.
[?] Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act [?] Company is reporting under Regulation A (Tier 2)
[?] Other (describe)
EXEMPT FROM SEC REGISTRATION/NO SEC REPORTING OBLIGATIONS:
[?] Company is exempt from registration under Exchange Act Rule 12g3-2(b)
[?] Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
[?] Company is reporting under the Alternative Reporting Company Disclosure Guidelines and is otherwise exempt from registration and not required to file periodic reporting
2. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC’s EDGAR system or the OTC Disclosure & News Service, as applicable.
3. The company is duly organized, validly existing and in good standing under the laws of Delaware in which the Company is organized or does business.
4. The share information below is for the primary OTCQB traded security as of the latest practicable date:
US Trading Symbol
RXMD
Shares Authorized
(A)
100,000,000
Total Shares Outstanding
(B)
6,240,731
Number of Restricted Shares1
(C)
3,400,333
Unrestricted Shares Held by Officers, Directors, 10% Control Persons & Affiliates
(D)
5,000
Public Float: Subtract Lines C and D from Line B
(E)
2,835,398
% Public Float: Line E Divided by Line B (as a %)2
(F)
45%
Number of Beneficial Shareholders of at least 100 shares3
(G) 1,029
As of (date): 3/29/2024 3/29/2024 3/29/2024 3/29/2024
3/29/2024 3/29/2024 12/31/2023
1 Restricted Shares means securities that are subject to resale restrictions for any reason. Your transfer agent should be able to provide the total number of restricted securities.
2 Public Float means the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a “10 percent Control Person”), or any Affiliates thereof, or any Family Members of officers,
directors, and control persons. Family Member shall mean a Person's spouse, parents, children, and siblings, whether by blood, marriage or adoption, or anyone residing in such Person's home. OTCQB traded securities are required to have a freely traded public float of at least 10% of the shares outstanding unless an exemption applies.
3 Beneficial Shareholder means any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security. OTCQB traded securities are required to have at least 50 beneficial shareholders unless an exemption applies.
OTC Markets Group Inc. OTCQB Certification (v. 3.2 March 7, 2023)
5.
Convertible Debt:
The following is a complete list of all promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities that were issued or outstanding at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification. (If the note is no longer outstanding as of the current date, but was outstanding during the previously described timeframe, the note must still be disclosed in the table below.):
[?] Check this box if there were no promissory notes, convertible notes, or other convertible debt arrangements issued or outstanding at any point during this time period.
Date of Note Issuance
Principal Amount at Issuance ($)
Outstanding Balance ($)4
Maturity Date
Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)
# Shares Converted to Date
# of Potential Shares to be Issued Upon Conversion5
Name of Noteholder (entities must have individual with voting / investment control disclosed).6
Reason for Issuance (e.g., Loan, Services, etc.)
8/30/2022
$2,790,886
$0
8/31/2027
Mandatory conversion upon the later to occur of (a) the completion of the Company’s reverse stock split, and (b) the listing of the Company’s common stock on a national exchange, including the Nasdaq Capital Market, the Nadaq Global Market, or the New York Stock Exchange
1,312,379
0
NextPlat Investors – control person, NextPlat Corp.
Loan (1)
11/16/2022
$10,000,000
$0
11/16/2025
Voluntary conversion at the option of the Holder, at any time and from time to time by delivering to the Company a Notice of Conversion specifying the principal amount to be converted, which is due and payable and the date on which such conversion shall be effected.
0
1,916,667
NextPlat Corp – control person, Charles M. Fernandez
Capital Raise
Total Outstanding Balance: 0 Total Shares: 1,312,379
Use the space below to provide any additional details, including footnotes to the table above:
(1) NextPlat Investors Note was converted on May 5, 2023. The outstanding balance of $2,887,229 as of May 5, 2023 included accrued interest of $92,343.
4 The Outstanding Balance is to include accrued interest.
5 The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any “blockers” or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.
6 International Reporting Companies may elect not to disclose the names of noteholders who are non-affiliates of the company. “Affiliate” is a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, an officer, a director, or a shareholder beneficially owning 10 percent or more of the Company’s outstanding shares.
OTC Markets Group Inc. OTCQB Certification (v. 3.2 March 7, 2023)
6. The following is a complete list of any law firm(s) and attorney(s) that acted as the Company’s primary legal counsel in preparing its most recent annual report. Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel. (If no attorney assisted in putting together the disclosure, identify the person(s) who prepared the disclosure and their relationship to the company.) Please also identify any other attorney, if different than the primary legal counsel, that assisted the company during the prior fiscal year on any matter including but not limited to, preparation of disclosure, press releases, consulting services, corporate action or merger assistance, etc.
Lucosky Brookman LLP: Joseph M. Lucosky, Esq.; Scott E. Linsky, Esq.
7. The following is a complete list of third-party providers, engaged by the Company, its officers, directors or controlling shareholders, at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, consulting, stock promotion, or any other related services to the Company. Please include the following items in this list: firm name, firm address, primary contact name and description of services provided. If none, please state “None”.
InvestorBrandNetwork (IBN) 8033 Sunset Blvd
Suite 1037
Los Angeles, CA 90046 Investor relations services
Cision US Inc.
300 S Riverside Plaza Chicago, IL 60606 Investor relations services
MWGCO, Inc.
16 Tioga Drive
Jericho, NY 11753 Investor relations services
8. Officers, Directors and 5% Control Persons:
The following is a complete list of Officers, Directors and 5% Control Persons (control persons are beneficial owners of five percent (5%) or more of any class of the issuer’s equity securities), including name, address, and number of shares owned. Preferred shares, options, warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities. If the corporate entity owning 5% or more does not have a person(s) owning or controlling it, provide a note explaining why. For nominee accounts owning 5% or more, provide the name of the 5% beneficial shareholder for this account. If there are no beneficial shareholders of 5% or more behind a nominee account, add a note confirming this.
Rodney Barreto
Name (First, Last)
Charles M. Fernandez
Pamela Roberts, PharmMD
Position/company affiliation
(ex: CEO, 5% control person)
Chairman of the Board of Directors and Chief Executive Officer
Vice Chairman of the Board of Directors
Chief Operating Officer
City and State
(and Country if outside US)
Coral Gables, FL
Coral Gables, FL
Hallandale Beach, FL
Number of Shares Owned
(list common, preferred, warrants and options separately)
480,446(1) 157,203(2)
414,547(3) 125,762(4)
3,522
Class of shares owned
Common Stock
Common Stock
Common Stock
Percentage of Class of Shares Owned (undiluted)
Cecile Munnik
Chief Financial Officer
Hallandale Beach, FL
10.0% 8.5% 0.1%
5,000 Common Stock 0.5% 25,000(5)
OTC Markets Group Inc.
OTCQB Certification (v. 3.2 March 7, 2023)
Jervis Hough
Director
Hallandale Beach, FL
42,957
Common Stock
Joseph Ziegler
Director
Hallandale Beach, FL
32,126
Common Stock
Pedro Rodriguez
Director
Hallandale Beach, FL
31,667
Common Stock
Elizabeth Alcaine
Director
Hallandale Beach, FL
8,897
Common Stock
Anthony Armas
Director
Hallandale Beach, FL
8,897
Common Stock
NextPlat Corp
Controlling Person-Charles M. Fernandez
3250 Mary St., Suite 410 Coconut Grove, FL 33133
1,703,520(6) 1,500,000(7) 1,500,000(8)
Common Stock
NextPlat Corp.
Controlling Person-Charles M. Fernandez
3250 Mary St., Suite 410 Coconut Grove, FL 33133
3,000
Series B Preferred Stock
Dawson James Securities, Inc.
Controlling Person-Robert D. Keyser Jr. and James Hopkins
101 N. Federal Hwy., Suite 600 Boca Raton, FL 33432
471,500(9)
Common Stock
Sixth Borough Capital Find, LP
Controlling Person – Robert D. Keyser Jr.
1515 N. Federal Highway, Suite 300, Boca Raton, FL 33432
246,501(10) 228,240(11)
Common Stock
Armen Karapetyan
Control person
3742 NE 208th St., Aventura, FL 33180
260,846(12) 90,000(11)
0.7% 0.5% 0.5% 0.1% 0.1% 60.9%
100% 7.0%
7.4% Common Stock 5.6%
Use the space below to provide any additional details, including conversion terms of any class of the issuer’s equity securities:
Share information as of March 27, 2024, as disclosed in our most recent Annual Report on Form 10-K for the year
ending December 31, 2023.
(1) Fully vested shares of common stock, including 462,185 shares of common stock owned by eAperion Partners,
LLC, of which Mr. Fernandez is the owner.
(2) Unexercised fully vested stock options to acquire 157,203 shares of common stock.
(3) Fully vested shares of common stock.
(4) Unexercised fully vested stock options to acquire 125,762 shares of common stock.
(5) Unexercised fully vested stock options to acquire 25,000 shares of common stock.
(6) Fully vested shares of common stock.
(7) 3,000 convertible Series B Preferred Stock convertible into 1,500,000 shares of our common stock underlying a
warrant.
(8) 3,000 convertible Series B Preferred Stock convertible into 1,500,000 shares of our common stock.
(9) Shares of our common stock underlying a warrant.
(10)Fully vested shares of common stock.
(11)Shares of our common stock underlying a warrant.
(12)Fully vested shares of common stock, including 29,323 shares of common stock owned by Spark Financial
Consulting, of which Mr. Karapetyan is the owner.
9. Certification:
Date: 05/01/2024
Name of Certifying CEO or CFO: Cecile Munnik
Title: Chief Financial Officer
Signature: /s/ CECILE MUNNIK
(Digital Signatures should appear as “/s/ [OFFICER NAME]”)
lol, that would be impressive, and I would Be sad for him at the same time
Not necessarily. Another RS and its over.
Yeah I'm just sitting and waiting. But that is a slippery slope in life. I've done it with things other than stock.
Take care Yoop
I have 3 tickers in my account, never sold, but it is definitely over for them/me. I'm hoping this doesn't become #4. Never "invest" in the OTC, just use lotto money.
It's not over till you sell. Have faith.
I also miss the money that used to be in my account
I guess I missed it too.
Did I miss a political argument while I was gone? Hopefully we get a good quarterly and it livens things up. Maybe some unexpected news too.
By my estimates, a couple billion.
Just out of curiosity Gedi, how many shares do you have now?
I hate partial orders. I should have put an A or N order.
Followers
|
746
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
194421
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |